The Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer

참고문헌 (171)

1. Lowenfels AB, "Epidemiology and prevention of pancreatic cancer", Jpn J Clin Oncol, 34, pp.238~244 (2004)
2. Moskaluk CA, "p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma", Cancer Res, 57, pp.2140~2143 (1997)
3. Hruban RH, "Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions", Am J Surg Pathol, 25, pp.579~586 (2001)
4. Dang CX, "Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer", Hepatobiliary Pancreat Dis Int, 1, pp.302~305 (2002)
5. Dergham ST, "Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma", Int J Pancreatol, 21, pp.127~143 (1997)
6. Dong M, "Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes", J Surg Oncol, 95, pp.332~336 (2007)
7. Bloomston M, "Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique", Dig Surg, 23, pp.74~79 (2006)
8. Dugan MC, "HER-2", neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival, 1997, pp.14, 229~236
9. Schutte M, "DPC4 gene invarious tumor types", Cancer Res, 56, pp.2527~2530 (1996)
10. Hua Z, "Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma", World J Gastroenterol, 9, pp.2764~2767 (2003)
11. Lumadue JA, "Familial pancreatic cancer and the genetics of pancreatic cancer", Surg Clin North Am, 75, pp.845~855 (1995)
12. Almoguera C, "Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes", Cell, 53, pp.549~553 (1988)
13. Smit VT, "KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas", Nucleic Acids Res, 16, pp.7772~7782 (1988)
14. Hruban RH, "K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination ofmutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization", Am J Pathol, 143, pp.545~554 (1993)
15. van Heek T, "K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis", Am J Clin Pathol, 117, pp.755~765 (2002)
16. Rozenblum E, "Tumor-suppressive pathways in pancreatic carcinoma", Cancer Res, 57, pp.1731~1734 (1997)
17. Kawesha A, "K-ras oncogene subtype mutations are associated with survivalbut not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma", Int J Cancer, 89, pp.469~474 (2000)
18. Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
19. Di Fiore F, "Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy", Br J Cancer, 96, pp.1166~1169 (2007)
20. Schutte M, "Abrogation of the Rb", p16 tumor-suppressive pathway in virtually all pancreatic carcinomas, 1997, pp.57, 3126~3130
21. Huang L, "Deletion and mutation analyses of the P16", MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas, 1996, pp.56, 1137~1141
22. Hu YX, "Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma", Clin Cancer Res, 3, pp.1473~1477 (1997)
23. Naka T, "Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer", Int J Oncol, 12, pp.1111~1116 (1998)
24. Garcea G, "Molecular prognostic markers in pancreatic cancer: a systematiceview", Eur J Cancer, 41, pp.2213~2236 (2005)
25. Barton CM, "Abnormalities of the p53 tumour suppressor gene in human pancreaticcancer", Br J Cancer, 64, pp.1076~1082 (1991)
26. Dong M, "Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer", World J Gastroenterol, 11, pp.2162~2165 (2005)
27. Morton JP, "Mutant p53 drives metastasis and overcomes growth arrest", senescence in pancreatic cancer, 2010, pp.107, 246~251
28. Lowe SW, "p53-dependent apoptosis modulates the cytotoxicity of anticancer agents", Cell, 74, pp.957~967 (1993)
29. Lowe SW, "Cancer therapy and p53", Curr Opin Oncol, 7, pp.547~553 (1995)
30. Sun Y, "p53 and its downstream proteins as molecular targets of cancer", Mol Carcinog, 45, pp.409~415 (2006)
31. Nakamori S, "Association of p53 gene mutations with short survival in pancreatic adenocarcinoma", Jpn J Cancer Res, 86, pp.174~181 (1995)
32. Dong M, "p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer", J Surg Oncol, 82, pp.111~120 (2003)
33. Gerdes B, "p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb", Ann Surg, 235, pp.51~59 (2002)
34. Salek C, "Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer", Anticancer Res, 29, pp.1803~1810 (2009)
35. Massague J, "TGFbeta signaling in growth control, cancer, and heritable disorders", Cell, 103, pp.295~309 (2000)
36. Miyaki M, "Role of SMAD4 (DPC4) inactivation in human cancer", Biochem Biophys Res Commun, 306, pp.799~804 (2003)
37. Wilentz RE, "Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression", Cancer Res, 60, pp.2002~2006 (2000)
38. Yachida S, "The pathology and genetics of metastatic pancreatic cancer", Arch Pathol Lab Med, 133, pp.413~422 (2009)
39. Tascilar M, "The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma", Clin Cancer Res, 7, pp.4115~4121 (2001)
40. Biankin AV, "DPC4", SMAD4 expression and outcome in pancreatic ductal adenocarcinoma, 2002, pp.20, 4531~4542
41. Khorana AA, "Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer", J Gastrointest Surg, 9, pp.903~911 (2005)
42. Iacobuzio-Donahue CA, "DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer", J Clin Oncol, 27, pp.1806~1813 (2009)
43. Schwarte-Waldhoff I, "SMAD4", DPC4-mediated tumor suppression through suppression of angiogenesis, 2000, pp.97, 9624~9629
44. Hahn SA, "BRCA2 germline mutations in familial pancreatic carcinoma", J Natl Cancer Inst, 95, pp.214~221 (2003)
45. Lal G, "Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations", Cancer Res, 60, pp.409~416 (2000)
46. Murphy KM, "Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%", Cancer Res, 62, pp.3789~3793 (2002)
47. Couch FJ, "The prevalence of BRCA2 mutations in familial pancreatic cancer", Cancer Epidemiol Biomarkers Prev, 16, pp.342~346 (2007)
48. Goggins M, "Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas", Cancer Res, 56, pp.5360~5364 (1996)
49. Real FX, "Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer", Gut, 50, pp.653~657 (2002)
50. Tsiambas E, "HER2", neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis, 2006, pp.7, 283~294
51. Safran H, "Overexpression of the HER-2", neu oncogene in pancreatic adenocarcinoma, 2001, pp.24, 496~499
52. Talar-Wojnarowska R, "Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis", Int J Gastrointest Cancer, 35, pp.33~41 (2005)
53. Yamanaka Y, "Overexpression of HER2", neu oncogene in human pancreatic carcinoma, 1993, pp.24, 1127~1134
54. Stoecklein NH, "Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma", J Clin Oncol, 22, pp.4737~4745 (2004)
55. Wang Z, "Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells", Cancer Res, 66, pp.2778~2784 (2006)
56. Wang Z, "Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells", Mol Cancer Ther, 5, pp.483~493 (2006)
57. Wang Z, "Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells", Cancer, 106, pp.2503~2513 (2006)
58. Wang Z, "Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells", Int J Cancer, 118, pp.1930~1936 (2006)
59. Buchler P, "The Notch signaling pathway is related to neurovascular progression of pancreatic cancer", Ann Surg, 242, pp.791~800 (2005)
60. Bailey JM, "Sonic hedgehog promotes desmoplasia in pancreatic cancer", Clin Cancer Res, 14, pp.5995~6004 (2008)
61. Walter K, "Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts", Clin Cancer Res, 16, pp.1781~1789 (2010)
62. Taketo MM, "Cyclooxygenase-2 inhibitors in tumorigenesis (part I)", J Natl Cancer Inst, 90, pp.1529~1536 (1998)
63. Albazaz R, "Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer", Pancreatology, 5, pp.361~369 (2005)
64. Juuti A, "Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer", J Clin Pathol, 59, pp.382~386 (2006)
65. Okami J, "Overexpression of cyclooxygenase-2 in carcinoma of the pancreas", Clin Cancer Res, 5, pp.2018~2024 (1999)
66. Maitra A, "Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging", Am J Clin Pathol, 118, pp.194~201 (2002)
67. Cheng JQ, "Amplification ofAKT2 in human pancreatic cells and inhibition of AKT2expression and tumorigenicity by antisense RNA", Proc Natl Acad Sci U S A, 93, pp.3636~3641 (1996)
68. Chadha KS, "Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma", Ann Surg Oncol, 13, pp.933~939 (2006)
69. Fahy BN, "AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2", Br J Cancer, 89, pp.391~397 (2003)
70. Lebe B, "The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas", Pathol Res Pract, 200, pp.389~396 (2004)
71. Ebert MP, "Induction and expression of cyclin D3 in human pancreatic cancer", J Cancer Res Clin Oncol, 127, pp.449~454 (2001)
72. Ito Y, "Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma", Anticancer Res, 21, pp.1043~1048 (2001)
73. Andrianifahanana M, "Mucin (MUC) gene expression in human pancreatic adenocarcinomaand chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance", Clin Cancer Res, 7, pp.4033~4040 (2001)
74. Arumugam T, "S100P promotes pancreatic cancer growth, survival, and invasion", Clin Cancer Res, 11, pp.5356~5364 (2005)
75. Goicoechea SM, "Isoform-specific upregulation of palladin in human and murine pancreas tumors", PLoS One, 5, pp.e10347~ (2010)
76. Salaria SN, "Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells", Cancer Biol Ther, 6, pp.324~328 (2007)
77. Zhang Y, "Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis", World J Surg, 33, pp.698~709 (2009)
78. Li A, "Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a", 200b in association with elevated circulating miR-200a and miR-200b levels, 2010, pp.70, 5226~5237
79. Rachagani S, "MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications", Cancer Lett, 292, pp.8~16 (2010)
80. Ho AS, "Circulating miR-210 as a novel hypoxia marker in pancreatic cancer", Transl Oncol, 3, pp.109~113 (2010)
81. Uwagawa T, "Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation", Anticancer Res, 29, pp.3173~3178 (2009)
82. Morton JP, "Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis", Proc Natl Acad Sci U S A, 104, pp.5103~5108 (2007)
83. Thayer SP, "Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis", Nature, 425, pp.851~856 (2003)
84. Nakashima H, "Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer", Cancer Res, 66, pp.7041~7049 (2006)
85. Gong YL, "Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer", J Surg Oncol, 73, pp.95~99 (2000)
86. Juuti A, "Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer", Oncology, 71, pp.61~68 (2006)
87. Jalanko H, "Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases", J Clin Pathol, 37, pp.218~222 (1984)
88. Steinberg W, "The clinical utility of the CA 19-9 tumor-associated antigen", Am J Gastroenterol, 85, pp.350~355 (1990)
89. Locker GY, "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer", J Clin Oncol, 24, pp.5313~5327 (2006)
90. Saif MW, "Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting"", JOP, 9, pp.398~402 (2008)
91. Nagata K, "Mucin expression profile in pancreatic cancer and the precursor lesions", J Hepatobiliary Pancreat Surg, 14, pp.243~254 (2007)
92. Yonezawa S, "The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms", J Hepatobiliary Pancreat Surg, 9, pp.328~341 (2002)
93. Ueda M, "MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT)", Hepatogastroenterology, 52, pp.398~403 (2005)
94. Swartz MJ, "MUC4 expression increases progressively in pancreatic intraepithelial neoplasia", Am J Clin Pathol, 117, pp.791~796 (2002)
95. Chaturvedi P, "MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins", Mol Cancer Res, 5, pp.309~320 (2007)
96. Saitou M, "MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas", J Clin Pathol, 58, pp.845~852 (2005)
97. Singh AP, "Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis", Cancer Res, 64, pp.622~630 (2004)
98. Ng SS, "Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma", Mol Cancer Ther, 1, pp.777~783 (2002)
99. Moore MJ, "Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 25, pp.1960~1966 (2007)
100. Wacker B, "Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies", Clin Cancer Res, 13, pp.3913~3921 (2007)
101. Starling N, "Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer", J Clin Oncol, 27, pp.5499~5505 (2009)
102. Watkins DJ, "The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study", ASCO Meeting Abstracts, 28, pp.4036~ (2010)
103. Ignatiadis M, "A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced", metastatic pancreatic cancer, 2006, pp.71, 159~163
104. Brell JM, "Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer", Oncology, 76, pp.270~274 (2009)
105. Fountzilas G, "Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation", Cancer Invest, 26, pp.784~793 (2008)
106. Safran H, "Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study", ASCO Meeting Abstracts, 27, pp.e15653~ (2009)
107. Safran H, "Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2", neu, 2004, pp.22, 706~712
108. Xiong HQ, "Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial", J Clin Oncol, 22, pp.2610~2616 (2004)
109. : SWOG S0205 study, "ASCO Meeting Abstracts", 2007, LBA4509~
110. Lee F, "Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer", ASCO Meeting Abstracts, 25, pp.15180~ (2007)
111. ) versus gemcitabine(G) as first-line treatment for metastatic pancreaticadenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4, "ACCORD 11 trial", ASCOMeeting Abstracts, 28, pp.4010~ (2010)
112. Egawa S, "The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR", Gastroenterology, 108, pp.1526~1533 (1995)
113. Itakura J, "Enhanced expressionof vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression", Clin Cancer Res, 3, pp.1309~1316 (1997)
114. Kindler HL, "A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabineplus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B CALGB", ASCO Meeting Abstracts, 25, pp.4508~ (2007)
115. Conrad C, "Antiangiogenic and antitumor activity of a novel vascular endothelial growthfactor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model", Anticancer Drugs, 18, pp.569~579 (2007)
116. Bramhall SR, "Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial", J Clin Oncol, 19, pp.3447~3455 (2001)
117. Bramhall SR, "A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer", Br J Cancer, 87, pp.161~167 (2002)
118. Moore MJ, "Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinomaof the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 21, pp.3296~3302 (2003)
119. Kilian M, "Matrix metalloproteinaseinhibitor RO 28-2653 decreases liver metastasisby reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer", Prostaglandins Leukot Essent Fatty Acids, 75, pp.429~434 (2006)
120. Cohen SJ, "Phase II and pharmacodynamic study of the farnesyltransferase inhibitorR115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma", J Clin Oncol, 21, pp.1301~1306 (2003)
121. Macdonald JS, "A phase IIstudy of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study", Invest New Drugs, 23, pp.485~487 (2005)
122. Van Cutsem E, "Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer", J Clin Oncol, 22, pp.1430~1438 (2004)
123. Liu M, "Antitumor activity ofSCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice", Cancer Res, 58, pp.4947~4956 (1998)
124. Eskens FA, "Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors", J Clin Oncol, 19, pp.1167~1175 (2001)
125. Awada A, "Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours", Eur J Cancer, 38, pp.2272~2278 (2002)
126. Raut CP, "Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts", Cancer Biol Ther, 3, pp.1217~1224 (2004)
127. Wei D, "Celecoxib inhibits vascular endothelial growth factor expressionin and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcriptionfactor activity", Cancer Res, 64, pp.2030~2038 (2004)
128. Blanquicett C, "Antitumorefficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects", Clin Cancer Res, 11, pp.8773~8781 (2005)
129. El-Rayes BF, "Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines", Mol Cancer Ther, 3, pp.1421~1426 (2004)
130. Ali S, "Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy", Mol Cancer Ther, 4, pp.1943~1951 (2005)
131. Lev-Ari S, "Curcumin synergisticallypotentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells", Biomed Pharmacother, 59(Suppl 2), pp.S276~S280 (2005)
132. Milella M, "Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma", Cancer, 101, pp.133~138 (2004)
133. Pino MS, "Capecitabine and celecoxib as second-line treatment of advanced pancreaticand biliary tract cancers", Oncology, 76, pp.254~261 (2009)
134. Kerr S, "Phase II trial of gemcitabine and irinotecanplus celecoxib in advanced adenocarcinoma of the pancreas", ASCO Meeting Abstracts, 23, pp.4155~ (2005)
135. Lipton A, "Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer", J Clin Gastroenterol, 44, pp.286~288 (2010)
136. El-Rayes BF, "A phase II study of celecoxib, gemcitabine, and cisplatin in advancedpancreatic cancer", Invest New Drugs, 23, pp.583~590 (2005)
137. Dragovich T, "Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial", Am J Clin Oncol, 31, pp.157~162 (2008)
138. Caldwell B, "Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis", J R Soc Med, 99, pp.132~140 (2006)
139. White WB, "Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials", Am J Cardiol, 99, pp.91~98 (2007)
140. Chen LC, "Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials", Pharmacoepidemiol Drug Saf, 16, pp.762~772 (2007)
141. Kearney PM, "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increasethe risk of atherothrombosis? Meta-analysis of randomisedtrials", BMJ, 332, pp.1302~1308 (2006)
142. Dhillon N, "Phase II clinical trial of curcumin in patients with advanced pancreatic cancer", ASCO Meeting Abstracts, 24, pp.14151~ (2006)
143. Strimpakos AS, "Curcumin: preventive and therapeutic properties in laboratory studies and clinicaltrials", Antioxid Redox Signal, 10, pp.511~545 (2008)
144. Kunnumakkara AB, "Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products", Cancer Res, 67, pp.3853~3861 (2007)
145. Banerjee S, "Molecular evidence forincreased antitumor activity of gemcitabine by genisteinin vitro and in vivo using an orthotopic model of pancreatic cance", Cancer Res, 65, pp.9064~9072 (2005)
146. Li Y, "Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells", Cancer Res, 65, pp.6934~6942 (2005)
147. El-Rayes BF, "Abbruzzese J,Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappa B", Cancer Res, 66, pp.10553~10559 (2006)
148. Grewe M, "Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells", Cancer Res, 59, pp.3581~3587 (1999)
149. Shah SA, "FRAP-p70s6K signaling is required for pancreaticcancer cell proliferation", J Surg Res, 97, pp.123~130 (2001)
150. Asano T, "The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation", Biochem Biophys ResCommun, 331, pp.295~302 (2005)
151. Ito D, "In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer", Int J Cancer, 118, pp.2337~2343 (2006)
152. Buck E, "Rapamycin synergizeswith the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors", Mol Cancer Ther, 5, pp.2676~2684 (2006)
153. Wolpin BM, "Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer", J Clin Oncol, 27, pp.193~198 (2009)
154. Gysin S, "Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1", Cancer Res, 65, pp.4870~4880 (2005)
155. Lorusso PM, "Phase I andpharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies", J Clin Oncol, 23, pp.5281~5293 (2005)
156. Rinehart J, "Multicenterphase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer", J Clin Oncol, 22, pp.4456~4462 (2004)
157. Moore PS, "Gene expression profiling after treatment with the histone deacetylase inhibitortrichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinomacells", Biochim Biophys Acta, 1693, pp.167~176 (2004)
158. Donadelli M, "Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells", Mol Carcinog, 38, pp.59~69 (2003)
159. Ryu JK, "SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines", Cancer Lett, 237, pp.143~154 (2006)
160. Sato N, "FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancercells", Int J Oncol, 24, pp.679~685 (2004)
161. Piacentini P, "Trichostatin A enhances the responseof chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation", Virchows Arch, 448, pp.797~804 (2006)
162. Donadelli M, "Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine", Biochim Biophys Acta, 1773, pp.1095~1106 (2007)
163. Arnold NB, "The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer", Clin Cancer Res, 13, pp.18~26 (2007)
164. Kumagai T, "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of humanpancreatic cancer cells", Int J Cancer, 121, pp.656~665 (2007)
165. Bai J, "Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells", Biochem Biophys Res Commun, 348, pp.1245~1253 (2006)
166. Hwang JH, "Cathepsin B is a target of Hedgehog signaling in pancreatic cancer", Cancer Lett, 273, pp.266~272 (2009)
167. Stanton BZ, "Small-molecule modulators of the Sonic Hedgehog signaling pathway", Mol Biosyst, 6, pp.44~54 (2010)
168. Feldmann G, "An orally bioavailable small-molecule inhibitor of Hedgehog signalinginhibits tumor initiation and metastasis in pancreatic cancer", Mol Cancer Ther, 7, pp.2725~2735 (2008)
169. Shafaee Z, "Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells", Cancer Chemother Pharmacol, 58, pp.765~770 (2006)
170. Hu WG, "Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells", Acta Pharmacol Sin, 28, pp.1224~1230 (2007)
171. Mueller MT, "Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer", Gastroenterology, 137, pp.1102~1113 (2009)

관련 논문AI추천